51762-05-1|Cefroxadine|(6R,7R)-7-((R)-2-amino-2-(cyclohexa-1,4-dien-1-yl)acetamido)-3-methoxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid|-范德生物科技公司

Cefroxadine

NMR下载 COA and HPLC MSDS下载
names：
(6R,7R)-7-((R)-2-amino-2-(cyclohexa-1,4-dien-1-yl)acetamido)-3-methoxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
CAS号：
51762-05-1
MDL Number：
MF(分子式)： C16H19N3O5S MW(分子量)： 365.404
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	Cefroxadine
英文别名	CGP 9000; CGP-9000; CGP9000; BRN 0587499; CXD; Cefroxadine. Oraspor
CAS号	51762-05-1
SMILES	O=C(C(N12)=C(OC)CS[C@]2([H])[C@H](NC([C@H](N)C3=CCC=CC3)=O)C1=O)O
Inchi	InChI=1S/C16H19N3O5S/c1-24-9-7-25-15-11(14(21)19(15)12(9)16(22)23)18-13(20)10(17)8-5-3-2-4-6-8/h2-3,6,10-11,15H,4-5,7,17H2,1H3,(H,18,20)(H,22,23)/t10-,11-,15-/m1/s1
InchiKey	RDMOROXKXONCAL-UEKVPHQBSA-N
分子式 Formula	C16H19N3O5S
分子量 Molecular Weight	365.404
闪点 FP
熔点 Melting point
沸点 Boiling point
Polarizability极化度
密度 Density
蒸汽压 Vapor Pressure
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	Cefroxadine(CAS:51762-05-1 ):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	Cefroxadine, also known as CGP 9000, is a cephalosporin antibiotic. It is structurally related to cefalexin, and both drugs share a similar spectrum of activity. It is available in Italy. Cefroxadine (CXD), an orally active cephalosporin antibiotic, has a broad spectrum and a bactericidal action. CXD showed excellent results in the treatment of acute uncomplicated cystitis (AUC).
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Kang YS, Lee SY, Kim NH, Choi HM, Park JS, Kim W, Lee HJ. A specific and rapid HPLC assay for the determination of cefroxadine in human plasma and its application to pharmacokinetic study in Korean. J Pharm Biomed Anal. 2006 Feb 13;40(2):369-74. Epub 2005 Aug 30. PubMed PMID: 16137854.

[2]Kitagawa S, Takeda J, Sato S. pH-dependent inhibitory effects of angiotensin-converting enzyme inhibitors on cefroxadine uptake by rabbit small intestinal brush-border membrane vesicles and their relationship with hydrophobicity and the ratio of zwitterionic species. Biol Pharm Bull. 1999 Jul;22(7):721-4. PubMed PMID: 10443470.

[3] Kitagawa S, Takeda J, Kaseda Y, Sato S. Inhibitory effects of angiotensin-converting enzyme inhibitor on cefroxadine uptake by rabbit small intestinal brush border membrane vesicles. Biol Pharm Bull. 1997 Apr;20(4):449-51. PubMed PMID: 9145229.

[4] Kitagawa S, Sugaya Y. Characteristics of uptake of cefroxadine by rabbit small intestinal brush border membrane vesicles. Biol Pharm Bull. 1996 Feb;19(2):268-73. PubMed PMID: 8850320.

[5] Beyssac E, Ritschel WA, Aiache JM, Haberer JP. Comparison of continuous, constant rate enteral tube feeding in supine patients to bolus food intake in ambulatory, healthy subjects regarding bioavailability of perorally administered cefroxadine. Methods Find Exp Clin Pharmacol. 1991 Nov;13(9):637-42. PubMed PMID: 1787771.

6: Beyssac E, Ritschel WA, Aiache JM, Haberer JP. Peroral absorption of cefroxadine in patients within the first day after severe trauma: comparison to cefroxadine pharmacokinetics in fasted, healthy volunteers. Methods Find Exp Clin Pharmacol. 1991 Oct;13(8):565-72. PubMed PMID: 1956212.7: Mendizabal MV, Idoate I, Jordan J, Larralde J. Effects of cefroxadine on L-leucine absorption in rat jejunum. Arch Int Physiol Biochim Biophys. 1991 Jun;99(3):247-50. PubMed PMID: 1717060.8: Cadórniga R, Molina IT, Pastoriza P, Negro S, Evora CM, Gutierrez JA. Pharmacokinetics of cefroxadine after infusion to healthy volunteers. Int J Clin Pharmacol Ther Toxicol. 1990 Oct;28(10):435-9. PubMed PMID: 2258253.9: Shibl AM, Durgham SM. In-vitro evaluation of a new oral cephalosporin, cefroxadine (CGP 9000). J Chemother. 1990 Feb;2(1):8-10. PubMed PMID: 2332786.10: Scaglione F, Cattaneo G, Bianchi MM, Verdecchia P, Maresca V, Bichisao E, Fraschini F. Cefroxadine in the treatment of children affected by respiratory and ENT diseases. A multicentre study involving 1072 in-patients. Drugs Exp Clin Res. 1989;15(2):71-6. PubMed PMID: 2737082.1

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开